SNIPR Biome, a Copenhagen-based clinical-stage biotech developing CRISPR-based microbial gene therapies, has secured €35 million in a Series B round.
The raise includes new backers Cystic Fibrosis Foundation and Germany’s Federal Agency for Breakthrough Innovation (SPRIN-D), alongside existing investors Lundbeckfonden BioCapital, North-East Family Office, and Wellington Partners.
The funding follows an earlier €20 million venture debt deal with the European Investment Bank in late 2024.
Targeting cystic fibrosis infections and antibiotic resistance genes
The fresh capital will be used to:
- Advance a CRISPR-Cas therapy for Pseudomonas aeruginosa airway infections in cystic fibrosis patients
- Develop interventions to eliminate antibiotic resistance genes across bacterial species in humans
- Progress SNIPR001, its lead therapeutic for preventing bloodstream infections in hematologic cancer patients, currently in Phase 1b trials at eight U.S. cancer centers
SNIPR Biome is also collaborating with CARB-X, the Gates Foundation, IPATH, SPRIN-D, and MD Anderson Cancer Center.
Advertisement
First to bring CRISPR medicine to human trials
Founded by Christian Grøndahl, SNIPR Biome was the first company to orally dose humans with a CRISPR therapeutic and holds both U.S. and European patents for microbiome-targeted CRISPR applications.
Its precision approach enables the selective killing of harmful bacteria or modification of microbial genes without disturbing healthy microbiota.
“This financing marks a pivotal milestone as we advance SNIPR001 and expand our infectious disease pipeline targeting high-priority pathogens,” said Grøndahl, CEO and co-founder.
Positioned at the forefront of infectious disease innovation
With antimicrobial resistance projected to cause 10 million deaths annually by 2050, SNIPR Biome aims to redefine how infectious diseases are treated — replacing broad-spectrum antibiotics with targeted, gene-editing-based interventions.
